- Home
- ALL vs ARGX Comparison
ALL vs ARGX Comparison
Compare ALL & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALL
- ARGX
- Stock Information
- Founded
- ALL 1931
- ARGX 2008
- Country
- ALL United States
- ARGX Netherlands
- Employees
- ALL N/A
- ARGX N/A
- Industry
- ALL Property-Casualty Insurers
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALL Finance
- ARGX Health Care
- Exchange
- ALL Nasdaq
- ARGX Nasdaq
- Market Cap
- ALL 53.1B
- ARGX 48.2B
- IPO Year
- ALL 1993
- ARGX 2017
- Fundamental
- Price
- ALL $193.85
- ARGX $812.69
- Analyst Decision
- ALL Buy
- ARGX Strong Buy
- Analyst Count
- ALL 15
- ARGX 18
- Target Price
- ALL $227.07
- ARGX $813.82
- AVG Volume (30 Days)
- ALL 1.3M
- ARGX 352.6K
- Earning Date
- ALL 11-05-2025
- ARGX 10-30-2025
- Dividend Yield
- ALL 2.07%
- ARGX N/A
- EPS Growth
- ALL 93.10
- ARGX N/A
- EPS
- ALL 21.24
- ARGX 18.75
- Revenue
- ALL $66,218,000,000.00
- ARGX $3,120,821,000.00
- Revenue This Year
- ALL N/A
- ARGX $81.74
- Revenue Next Year
- ALL $6.63
- ARGX $31.91
- P/E Ratio
- ALL $9.10
- ARGX $39.03
- Revenue Growth
- ALL 9.81
- ARGX 88.04
- 52 Week Low
- ALL $176.00
- ARGX $510.06
- 52 Week High
- ALL $215.70
- ARGX $855.46
- Technical
- Relative Strength Index (RSI)
- ALL 34.83
- ARGX 58.92
- Support Level
- ALL $191.87
- ARGX $807.42
- Resistance Level
- ALL $196.11
- ARGX $855.46
- Average True Range (ATR)
- ALL 3.70
- ARGX 16.57
- MACD
- ALL -1.56
- ARGX -2.36
- Stochastic Oscillator
- ALL 8.90
- ARGX 41.12
About ALL Allstate Corporation (The)
Allstate is one of the largest US property-casualty insurers in the US. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 6,000 exclusive agents.
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.